NASDAQ$INO
Inovio Pharmaceuticals Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Inovio reported financial results and operational highlights.
Inovio reported a net loss of $40.6 million, or $0.16 per share, for the quarter ended March 31, 2023. The company ended the quarter with $223.8 million in cash, cash equivalents and short-term investments and expects its cash runway to extend into the first quarter of 2025.
- Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients.
- Announced positive data from Phase 1b trial with INO-4201 as an Ebola booster for ERVEBO®.
- Announced topline results for REVEAL2, the second Phase 3 trial for VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions.
- Ended the first quarter 2023 with $223.8 million in cash, cash equivalents and short-term investments.
Headline financials
Revenue & EPS history
Inovio · Revenue · Quarterly
$115K
Forward guidance
INOVIO continues to expect its cash runway to extend into the first quarter of 2025. This projection includes a cash burn estimate of approximately $33 million for the second quarter 2023 and its ongoing expectation that cash burn will decrease incrementally from there into the first quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-1.6%
Avg return
Earnings day
-0.6%
Avg return
5 days after
-5.9%
Avg return
30 days after
39%
25 / 64 earnings
Positive
+21.6%
Q4 2014
Best reaction
-27.8%
Q2 2013
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.3% | -13.5% | -22.0% | |
| Q4 2025 | -1.2% | -1.2% | -36.9% | |
| Q3 2025 | -7.1% | -4.7% | -0.9% | |
| Q1 2025 | -1.6% | +7.8% | +4.2% | |
| Q4 2024 | -6.7% | -10.5% | -17.1% | |
| Q3 2024 | -13.9% | -18.6% | -53.1% | |
| Q2 2024 | -1.7% | -8.1% | -26.9% | |
| Q1 2024 | +7.2% | +12.7% | -11.0% | |
| Q4 2023 | -6.7% | +24.4% | +21.9% | |
| Q3 2023 | -7.9% | +0.0% | +0.0% | |
| Q2 2023 | +9.5% | +9.5% | +7.1% | |
| Q1 2023 | -7.1% | -8.3% | -38.1% | |
| Q4 2022 | +3.2% | -4.0% | -34.9% | |
| Q3 2022 | +1.4% | +9.3% | -14.4% | |
| Q2 2022 | +10.2% | +11.4% | -8.5% | |
| Q1 2022 | -23.6% | -16.0% | -30.4% | |
| Q4 2021 | -5.9% | -4.0% | +10.8% | |
| Q3 2021 | +5.6% | +9.1% | -7.0% | |
| Q2 2021 | -5.9% | +1.3% | -9.2% | |
| Q1 2021 | -5.3% | -4.4% | +46.4% | |
| Q4 2020 | -9.7% | -17.2% | -16.4% | |
| Q3 2020 | +9.3% | +6.6% | +8.5% | |
| Q2 2020 | -27.7% | -26.9% | -49.2% | |
| Q1 2020 | +18.8% | +23.7% | +23.3% | |
| Q4 2019 | -14.0% | -12.3% | -3.0% | |
| Q3 2019 | -5.7% | -4.1% | +10.6% | |
| Q2 2019 | -1.6% | -6.3% | -15.8% | |
| Q1 2019 | -4.4% | -9.2% | -37.2% | |
| Q4 2018 | +3.7% | +0.0% | +15.9% | |
| Q3 2018 | +1.1% | -7.5% | -1.3% | |
| Q2 2018 | +14.3% | +13.8% | +35.5% | |
| Q1 2018 | -6.2% | +1.1% | -5.1% | |
| Q4 2017 | +6.6% | +12.6% | +11.5% | |
| Q3 2017 | -16.6% | -14.3% | -15.3% | |
| Q2 2017 | -0.2% | -1.4% | +7.8% | |
| Q1 2017 | +5.8% | +15.2% | +27.0% | |
| Q4 2016 | -6.1% | -7.7% | -7.9% | |
| Q3 2016 | +18.7% | +26.8% | +8.7% | |
| Q2 2016 | -8.1% | -9.1% | -8.1% | |
| Q1 2016 | +4.7% | — | — | |
| Q4 2015 | -4.9% | — | — | |
| Q3 2015 | +3.1% | — | — | |
| Q2 2015 | +20.5% | — | — | |
| Q1 2015 | +1.1% | — | — | |
| Q4 2014 | +21.6% | — | — | |
| Q3 2014 | +0.6% | — | — | |
| Q2 2014 | -12.9% | — | — | |
| Q1 2014 | +2.8% | — | — | |
| Q4 2013 | -2.0% | — | — | |
| Q3 2013 | -1.1% | — | — | |
| Q2 2013 | -27.8% | — | — | |
| Q1 2013 | +1.6% | — | — | |
| Q4 2012 | -1.9% | — | — | |
| Q3 2012 | -7.6% | — | — | |
| Q2 2012 | +1.9% | — | — | |
| Q1 2012 | -2.0% | — | — | |
| Q4 2011 | -6.5% | — | — | |
| Q3 2011 | -4.8% | — | — | |
| Q2 2011 | +1.7% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | -1.8% | — | — | |
| Q3 2010 | +5.9% | — | — | |
| Q2 2010 | -1.1% | — | — | |
| Q1 2010 | -7.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro